AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32167260
Drug: Ganglion cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglion cell complex thickness-to-total retinal thickness ratio (G/T ratio)
Trial: 32123969
Drug: octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octreotide LAR 60 mg
Trial: 35698187
Drug: Myofascial Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial Release Therapy
Trial: 35057905
Drug: Intravaginal lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal lactic acid gel (5 ml once daily for 7 days)
Trial: 35057905
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (400 mg twice daily for 7 days)
Trial: 33434727
Drug: Mindfulness-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based group therapy (MBGT) + Treatment-as-usual (TAU)
Trial: 36384950
Drug: Community-based education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based education and peer support programme led by women's self-help group members; assistance in daily hypertension management, social and emotional support, referral to primary healthcare system.
Trial: 32315289
Drug: Intragastric infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intragastric infusion of glucose
Trial: 32315289
Drug: Intragastric infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intragastric infusion of water
Trial: 32315289
Drug: Baseline levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline levels of peripheral appetite hormones
Trial: 34049538
Drug: Traditional one-year
RxNorm normalized name: segesterone
DrugBank: Segesterone (DB14584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional one-year family medicine residency program
Trial: 35380374
Drug: ON-SXB 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ON-SXB 7.5 g
Trial: 36216727
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of remifentanil dissolved in 25 ml of saline
Trial: 36216727
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of intra‐articular normal saline
Trial: 36316939
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine-based rehabilitation nursing combined with scalp acupuncture (TCMRN + SA)
Trial: 36316939
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine-based rehabilitation nursing (TCMRN)
Trial: 35677618
Drug: Siddha medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siddha medicine preparation (Nochi Kudineer Chooranam 5 gm, Mahasudarsan Chooranam 3 gm, Adathodai Manapagu 10 ml, Omatheeneer 10 ml, Maldevi chenduram 100 mg with honey) for 7 days
Trial: 34653721
Drug: Local Anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Anesthetic Injection (LAI)
Trial: 34653721
Drug: Intraperitoneal Local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal Local Anesthetic Injection (IPLA)
Trial: 34862871
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no targeted drug)
Trial: 35313949
Drug: treatment-as-usual +
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual + AppBM
Trial: 35313949
Drug: treatment-as-usual +
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual + Sham
Trial: 35313949
Drug: treatment-as-usual only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual only
Trial: 35277340
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus paracetamol
Trial: 35277340
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus morphine (control)
Trial: 33087171
Drug: Opioid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid treatment
Trial: 32835826
Drug: Alternative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative analgesic agents
Trial: 32453396
Drug: DHA (465
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (465 mg) plus vitamin E (600 IU)
Trial: 32453396
Drug: DHA (465
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (465 mg) plus placebo
Trial: 32453396
Drug: Both placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both placebo capsules
Trial: 32249311
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion
Trial: 35603411
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) 70 mL (400 mg of nitrate)
Trial: 32295483
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training (CT) programme for 12 weeks, 45 min twice a week
Trial: 32621465
Drug: Navigational dual-target
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navigational dual-target high-frequency rTMS (10 Hz) applied over the primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC) for 20 daily sessions over 3 weeks.
Trial: 32621465
Drug: Placebo rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rTMS (10 Hz) applied over the same areas for 20 daily sessions over 3 weeks.
Trial: 32937023
Drug: telmisartan/amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg
Trial: 32937023
Drug: telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg + rosuvastatin 20 mg
Trial: 32937023
Drug: telmisartan/amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan/amlodipine 80/5 mg
Trial: 33721444
Drug: Cetuximab combined
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with IMRT and concurrent cisplatin‐based chemotherapy
Trial: 33721444
Drug: IMRT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT combined with concurrent cisplatin‐based chemotherapy (Control group)
Trial: 35750460
Drug: Fosfomycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3 g single dose) and two placebo tablets three times a day for 7 days
Trial: 33938936
Drug: Nivolumab-Ipilimumab combination
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab-Ipilimumab combination therapy
Trial: 32366948
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori (Hp) sero-positivity with periodontal pathogens (e.g., Prevotella intermedia, Campylobacter Rectus, Actinomyces Naeslundii)
Trial: 32612574
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptive (COC)
Trial: 34610254
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% dosed twice daily
Trial: 36173041
Drug: Gluten-containing diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten-containing diet (14 g/day gluten for 14 days)
Trial: 33150745
Drug: GnRHAG (gonadotropin‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHAG (gonadotropin‐releasing hormone agonist) for 24 weeks (n = 14)
Trial: 35078574
Drug: Leptin (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin (50, 100, 200, 400 ng/mL)
Trial: 35078574
Drug: Leptin (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin (after knockdown of MMP14 and leptin receptor genes)
Trial: 35078574
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no leptin treatment)
Trial: 34939265
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ARS and Traditional Lecture
Trial: 33123587
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral Chinese and western medicine)
Trial: 35757326
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 mcg/kg/day subcutaneously)
Trial: 35757326
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of 0.9% saline subcutaneously)
Trial: 36287306
Drug: Berdazimer gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berdazimer gel, 10.3%
Trial: 32238014
Drug: Isotretinoin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (20 mg/d) plus topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Trial: 32238014
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Trial: 32737891
Drug: Self-report of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report of very poor/poor oral health
Trial: 32737891
Drug: Self-report of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report of fair oral health
Trial: 37267172
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (video DOT) for 12 weeks via a mobile health technology platform
Trial: 37267172
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (video DOT)
Trial: 32250672
Drug: Housing Prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing Prescriptions as Health Care (integrating priority placement in affordable housing and provision of services such as case management, financial, and legal services)
Trial: 36267872
Drug: Tropifexor 30
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 30 μg
Trial: 36267872
Drug: Tropifexor 60
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 60 μg
Trial: 36267872
Drug: Tropifexor 90
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 90 μg
Trial: 36267872
Drug: Tropifexor 150
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 150 μg
Trial: 36267872
Drug: Tropifexor (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor (all doses)
Trial: 36271352
Drug: Subcutaneous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ketamine (0.5 mg/kg)
Trial: 36271352
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (40-min infusion)
Trial: 34487870
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 4 or 8 weeks
Trial: 38115002
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine
Trial: 38695087
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter defibrillator (S-ICD)
Trial: 33964910
Drug: remestemcel‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remestemcel‐L
Trial: 36087586
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg R21/25 μg Matrix‐M
Trial: 36087586
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg R21/50 μg Matrix‐M
Trial: 36087586
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Rabivax‐S rabies vaccine)
Trial: 32449213
Drug: Lasmiditan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (50 mg, 100 mg, 200 mg)
Trial: 32449213
Drug: Lasmiditan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (100 mg, 200 mg)
Trial: 35998947
Drug: Meperidine-Ketorolac combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine-Ketorolac combination (1 mg/kg IV meperidine and 30 mg IV ketorolac)
Trial: 35998947
Drug: Meperidine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine alone (1 mg/kg IV meperidine)
Trial: 36361001
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (OT)
Trial: 34575292
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of clonidine 1 µg/kg and normal saline 0.9% (Group 2)
Trial: 34575292
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of normal saline 0.9% (Group 1)
Trial: 33333767
Drug: Bioactive compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive compounds enriched infant formula (EF)
Trial: 34358486
Drug: Probiotics (Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02, 2·5 × 10^9 colony-forming units per capsule, consumed twice per day for 8 weeks)
Trial: 34358486
Drug: Placebo (consumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (consumed twice per day for 8 weeks)
Trial: 32191532
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 µg/DRSP 3 mg
Trial: 32191532
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 µg/CMA 2 mg
Trial: 32191532
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 µg/DNG 2 mg
Trial: 37489374
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment
Trial: 32213105
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine at 6.5 mg/kg once every 3 weeks
Trial: 32213105
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine at 1.8 mg/kg once per week
Trial: 32213105
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine at 2.2 mg/kg once per week
Trial: 32213105
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine (various doses)
Trial: 32603560
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with aripiprazole
Trial: 32603560
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with bupropion
Trial: 34913294
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg twice daily)
Trial: 34913294
Drug: Ganirelix acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix acetate (0.25 mg subcutaneously daily)
Trial: 33491323
Drug: 1.5 oz
RxNorm normalized name: {1 (1.5 OZ Hydrocortisone 1 % Topical Gel) / 1 (60 GM Ketoconazole 2 % Topical Cream) } Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 oz of almonds daily for 12 weeks
Trial: 33491323
Drug: 1.8 oz
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Hand Sanitizer Original 1.8 oz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 oz of pretzels daily for 12 weeks
Trial: 32605655
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment group
Trial: 32605655
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment group
Trial: 35037386
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml minoxidil for external use twice a day
Trial: 35037386
Drug: 3500 IU
RxNorm normalized name: Lactic Acid/Vitamin E 10%-3500 IU/30 GM Topical application Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3500 IU basic fibroblast growth factor (bFGF) and 1 ml minoxidil for external use twice a day
Trial: 33161036
Drug: Microneedle (MN)
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle (MN) patch
Trial: 33161036
Drug: Microneedle patch
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle patch with needles laying flat (negative control)
Trial: 35676335
Drug: Nicotine transdermal
RxNorm normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine transdermal patch (14 mg daily)
Trial: 36245011
Drug: Weekly DPCP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly DPCP application
Trial: 33407828
Drug: Hochu‐ekki‐to (HET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hochu‐ekki‐to (HET) - 9 tablets, 2 times per day for 8 weeks
Trial: 33407828
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 9 tablets, 2 times per day for 8 weeks
Trial: 33155034
Drug: SaLeish vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaLeish vaccine (fusion protein of SP15 and LeIF)
Trial: 36179438
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavioral therapy (CBT) program
Trial: 33823560
Drug: Therapeutic-dose low
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg SQ/BID (CrCl ≥ 30 ml/min) or 0.5 mg/kg (CrCl 15-30 ml/min)
Trial: 33823560
Drug: Prophylactic/intermediate-dose LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic/intermediate-dose LMWH or unfractionated heparin (UFH)
Trial: 33823560
Drug: Therapeutic-dose LMWH
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose LMWH
Trial: 39338117
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy
Trial: 39076222
Drug: Tocovid capsules
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tocovid capsules
Trial: 36272277
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion of ampicillin/sulbactam (infused over 4 hours)
Trial: 36272277
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ampicillin/sulbactam (infused over 30 minutes)
Trial: 35396602
Drug: Domagrozumab (myostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab (myostatin inhibitor)
Trial: 32217791
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (PILL)
Trial: 32217791
Drug: Transdermal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal iron (PATCH)
Trial: 34903440
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments and care process (Control group).
Trial: 32385167
Drug: 12.7 g
RxNorm normalized name: potassium chloride 12.7 gram HEMODIALYS POWDER IN PACKET (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.7 g of MSG
Trial: 34206175
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (body weight, elastic bands, water canes) twice per week for eight months
Trial: 33051340
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Stereotactic Body Radiation Therapy (SBRT; 50 Gy in 4 fractions)